EN DE

Aoyuan Healthy Life Group (3662) Fair Value & Analysis

Real Estate · HK · Market cap HK$265M (≈ $33.8M) · ISIN KYG0404F1019

What is Aoyuan Healthy Life Group really worth?

AH Aoyuan Healthy Life Group 3662 · HK
PriceHK$0.3200
Fair ValueHK$0.2630
Upside−17.8%
Quality54/100

A solid business, but trading 22% above our fair value of HK$0.2630.

As of Aug 30, 2026, the fair value of Aoyuan Healthy Life Group is HK$0.2630 per share against a price of HK$0.3200, so the fair value sits 18% below the price. A model estimate blended from multiple valuation models, recalculated regularly.

Watch Aoyuan Healthy Life Group for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

Strengths

✓generates free cash flow

Risks

!Weak Growth (revenue 5y −2.8 %/yr)
!Thin margins · 4.2% net margin
!Mixed vs. peers (7/12)
!Narrow moat 29/100
!Evidence only low, so the estimate is less certain
!Weak on valuation: 8 out of 100
!Weak on past: 16 out of 100
Evidence: Low Range HK$0.2103 – HK$0.3288

Fair value as of: Aug 30, 2026

From 16 valuation models · updated 7 days ago

Fair value updated Aug 30, 2026, revised from HK$0.2633 to HK$0.2630 (−0.1%) since Aug 13, 2026. Share price −8.6% over the past month.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

  • Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder.
  • Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
  • As a real-estate business, asset- and dividend-based methods carry more weight here than a standard DCF.

Price vs Fair Value (5 years)

HK$6.62 HK$0.2700 Fair Value HK$0.2630 Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 30, 2026.

How to read this chart

60‑month range HK$0.2700 – HK$6.62 · fair‑value band HK$0.2103 – HK$0.3288 · the HK$0.3200 price screens above the HK$0.2630 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 30, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Aoyuan Healthy Life Group (3662) currently trades at HK$0.3200, while our model-based Fair Value estimate is HK$0.2630, implying the stock looks roughly 21.7% overvalued today. The Quality Score stands at 54/100 (solid quality), in the Real Estate sector. Bull case: the Growth DCF group reads highest at a median of HK$1.84 per share, and 14 of the 16 models we run sit above the HK$0.3200 price. Bear case: the Dividend Discount group reads lowest at HK$0.2500, and 2 of the 16 models stay below the price. Evidence for this calculation is low.

Over the trailing twelve months, Aoyuan Healthy Life Group generated revenue of HK$1.2B at a net margin of 4.2%. Revenue declined 7.1% year over year. It earns a return on equity of 3.9%. The balance sheet holds a net cash position of HK$942M. Fundamentals as of Aug 30, 2026

Our scenario range runs from HK$0.2103 (bear case) to HK$0.3288 (bull case); at HK$0.3200, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 48% below its 52-week high and 21% above its 52-week low, currently below its 200-day average. For context, the median of 10 Real Estate peers we cover trades at −23% fair-value upside, at −18%, 3662 screens cheaper than that median.

Fair Value models

This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly HK$0.0205 per share, which is 7.8 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
FCF DCF best evidence HK$1.74 HK$1.86 HK$2.00 80
Growth DCF HK$1.74 HK$1.84 HK$1.96 77
Residual Income HK$1.12 HK$1.08 HK$0.8600 76
All 16 models by family
DCF Models
FCF DCF best evidence HK$1.74 HK$1.86 HK$2.00 80
5Y Revenue Exit HK$2.19 HK$2.74 HK$3.43 71
5Y EBITDA Exit HK$2.57 HK$3.43 HK$4.42 74
10Y Revenue Exit HK$1.95 HK$2.35 HK$2.87 66
10Y EBITDA Exit HK$2.18 HK$2.75 HK$3.50 67
Dividend Discount
Gordon GGM HK$0.1800 HK$0.3000 HK$0.3900 68
DDM Multi-Stage HK$0.1800 HK$0.2500 HK$0.3200 67
Multiples
P/S Multiple HK$0.9100 HK$1.21 HK$1.51 58
P/B Multiple HK$0.9100 HK$1.21 HK$1.51 55
EV/EBIT HK$3.65 HK$4.41 HK$5.16 63
EV/EBITDA HK$3.51 HK$4.22 HK$4.93 64
EV/Revenue HK$2.64 HK$3.17 HK$3.71 52
Asset-Based
NCAV (Graham) HK$0.8300 HK$1.11 HK$1.66 51
Growth DCF
Growth DCF HK$1.74 HK$1.84 HK$1.96 77
Rev-Margin DCF HK$2.19 HK$2.73 HK$3.32 71
Economic Profit
Residual Income HK$1.12 HK$1.08 HK$0.8600 76

Widest divergence: Multiples (HK$3.17) versus Dividend Discount (HK$0.2500). Highest evidence: FCF DCF (80).

Notify me when 3662 reaches fair value

Put 3662 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Free, no payment details. Unsubscribe anytime in one click.

Key figures & financial health

P/E ratio 4.6 as of Jul 2, 2026
P/S ratio 0.19 P/E × margin
EPS (TTM) HK$0.0300 price ÷ EPS = P/E 4.6
Dividend yield 7.1% payout 75.4%
Net margin 4.2% FY2025
Return on equity 3.9% TTM
More key figures
Profitability
Return on assets (EBIT) 4.3% avg 5y
Operating margin 7.7% TTM
Growth
Revenue (TTM) HK$1.2B TTM
Revenue growth (YoY) −7.1% 3y avg −9.2%
EPS growth (YoY) +82.4%
Balance sheet & cash flow
Free cash flow HK$31.6M FY2025
Net cash HK$942M FY2025

Figures from reported company fundamentals · as of Aug 30, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 54/100

Of which business quality 57 · Market factors (momentum, volatility) 32

Profitability 29
Margins and returns on capital today
Quality Growth 26
Are margins and returns improving?
Cashflow 36
Earnings quality: real cash, not paper profit
Fin. Strength 95
Balance sheet, leverage, solvency risk
Investment 85
Disciplined investing over empire-building
Low Volatility 58
Calm price path (market factor)
Momentum 28
Price trend over the last 3–12 months (market factor)
52W Momentum 8
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

Starjoy Wellness and Travel Company Limited, through its subsidiaries, provides property management and commercial operational services in the People's Republic of China. The company operates through Property Management Services and Commercial Operational Services segments.

Full company description

Starjoy Wellness and Travel Company Limited, through its subsidiaries, provides property management and commercial operational services in the People's Republic of China. The company operates through Property Management Services and Commercial Operational Services segments. It offers property management services for residential communities, commercial complexes, office buildings, villas, and tourist towns; and sales assistance services, community value-added services, and heating services for both residential and non-residential units to property developers, property owners, and residents. The company also provides commercial operation and management services and market positioning, and business tenant sourcing services to commercial property developers and commercial property lessees. In addition, it engages in the operation of the mobile application; provision of cleaning and gardening, design management and consulting, decoration and furniture, engineering consulting, and health management services. The company was formerly known as Aoyuan Healthy Life Group Company Limited and changed its name to Starjoy Wellness and Travel Company Limited in January 2024. The company was founded in 2000 and is based in Guangzhou, the People's Republic of China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Aoyuan Healthy Life Group reported revenue of 1.2B CNY in FY2025 versus 1.9B CNY in FY2021, a compound −11.0%/yr. Reported net income was 51.6M CNY in FY2025.

Growth Quality 40/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
HK$1.2B
Latest YoY
−10.0%
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−9.2%
Avg. revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−2.8%
Avg. revenue growth/yr (10Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+21.1%
Value creation/yr (5Y) ⓘEarnings growth per share (CAGR 5 years) plus dividend yield: value created per share and year.
−17.5% · in HKD
Earnings growth per share plus dividend yield: the value created per share and year.
Earnings growth per share−24.6%
Dividend yield7.1%
Trend ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.5Y −24.6% vs 10Y 3.9%, flattening
Operating margin (EBIT) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.22.3% (2020) → 8.2% (2025) · falling
Worst earnings drop176% (2021) (loss year, drop beyond 100%) · in HKD
Revenue −11.0%/yr
FY21 1.9B CNY
FY22 1.6B CNY
FY23 1.6B CNY
FY24 1.4B CNY
FY25 1.2B CNY
Net income
FY21 −191M CNY
FY22 160M CNY
FY23 157M CNY
FY24 96.2M CNY
FY25 51.6M CNY
Character of growth · EPS growth decomposed (2015-2025) +13.3 % p.a.
Revenue per share +23.4 %

of which total revenue +23.9 % · buybacks/dilution −0.4 %

EBIT margin −8.7 %
Tax rate +1.0 %
Residual (interest, one-offs) −0.5 %

Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).

3662 screens 22% overvalued. Compare with CBRE Group →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Aoyuan Healthy Life Group · Fair Value
HK$0.2630 −22%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Aoyuan Healthy Life Group Fair Value". https://www.fairvalue-calculator.com/stock/3662.HK

Peer Group

Real Estate Services · 525 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 56 · Above median
Fair Value upside −19% · Below median
Return on equity (TTM) 4% · Below median
Return on assets 3% · Above median
Net margin (TTM) 4% · Below median
Operating margin (TTM) 8% · Below median
Revenue growth −7% · Below median
Dividend yield (TTM) 7.1% · Top 25%

Valuation Multiples vs Real Estate Services median · lower = cheaper

P/E (TTM) 4.6× · Cheaper than 75% of peers
P/B 0.22× · Cheaper than 75% of peers
P/S (TTM) 0.22× · Cheaper than 75% of peers
P/FCF 1.1× · Cheaper than median

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE8 · sector 29
FUTURE0 · sector 11
PAST16 · sector 17
HEALTH0 · sector 84
DIVIDEND100 · sector 63

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Real Estate Services stocks, each showing price versus our Fair Value estimate (as of Aug 30, 2026).

Stock Price Fair Value vs Fair Value
CBRE Group CBRE $148.74 $69.47 −53%
Vonovia SE VNA €19.85 €36.67 +85%
Cellnex Telecom, S.A CLNX €27.47 €25.46 −7%
KE Holdings BEKE $17.42 $6.57 −62%
Jones Lang LaSalle Incorporated JLL $378.01 $290.25 −23%
Swire Properties Limited 1972 HK$24.84 HK$5.12 −79%
CoStar Group CSGP $32.22 $4.64 −86%
China Resources Mixc Lifestyle Services Limited 1209 HK$39.84 HK$34.95 −12%
CapitaLand Investment Limited 9CI 2.66 SGD 0.4900 SGD −82%
Plaza S.A MALLPLAZA 4,040 CLP 4,571 CLP +13%

Compare Aoyuan Healthy Life Group with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Real Estate stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Extrinsic Value Calculator (Options) Splits an option premium into intrinsic and extrinsic (time) value. Peter Lynch Fair Value Formula & Calculator Apply Peter Lynch's fair value formula in seconds: fair P/E ≈ earnings growth (+ dividend) - free, with formula and example.

Frequently asked questions

Is Aoyuan Healthy Life Group (3662) overvalued or undervalued?
As of Aug 30, 2026, our model estimates a fair value of HK$0.2630 versus a price of HK$0.3200, about −18% upside (overvalued).
What is the fair value of 3662?
Our model-based fair value for Aoyuan Healthy Life Group is HK$0.2630 (as of Aug 30, 2026), built from audited fundamentals. The current price: HK$0.3200.
What is the quality score of 3662?
Aoyuan Healthy Life Group has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Aoyuan Healthy Life Group (3662)?
Our model-based price target is the fair value of HK$0.2630 (as of Aug 30, 2026) from 16 valuation models. Cautious scenario HK$0.2103, optimistic scenario HK$0.3288. It is a calculation from audited fundamentals, not an analyst target.
What is the Aoyuan Healthy Life Group stock forecast for 2026?
Our models put fair value at HK$0.2630, about −18% upside versus a price of HK$0.3200 (overvalued). Cautious scenario HK$0.2103, optimistic scenario HK$0.3288. The calculation is refreshed regularly with new filings.
What is the revenue of Aoyuan Healthy Life Group (3662)?
Aoyuan Healthy Life Group reported trailing-twelve-month revenue of about HK$1.2B (latest available figure, as of Aug 30, 2026).
What is the net profit margin of 3662?
The net profit margin of Aoyuan Healthy Life Group is about 4.2%, meaning it keeps roughly 4.2% of revenue as net income. Based on the latest reported figures.
Does Aoyuan Healthy Life Group pay a dividend?
Aoyuan Healthy Life Group currently shows a dividend yield of about 7.07% relative to its recent price (as of Aug 30, 2026).
Free · no account needed

Watch Aoyuan Healthy Life Group in the live analysis

One click puts Aoyuan Healthy Life Group on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.